Metabolomic analysis reveals the biological characteristics of giant congenital melanocytic nevi

被引:1
作者
Chang, Yajie [1 ]
Dai, Tao [2 ]
Song, Ge [1 ,3 ]
Wang, Sanxi [1 ]
Pei, Huile [4 ]
Shen, Guiping [1 ,5 ,6 ]
Feng, Jianghua [1 ]
机构
[1] Xiamen Univ, Dept Elect Sci, Fujian Prov Key Lab Plasma & Magnet Resonance, Xiamen 361005, Peoples R China
[2] Tongji Univ, Tongji Hosp, Dept Wound Reconstruct Surg, Shanghai 200065, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Plast Surg, Luoyang 471003, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 2, Dept Dermatol, Luoyang 471003, Peoples R China
[5] Tongji Hosp, 389Xincun Rd, Shanghai 200065, Peoples R China
[6] Xiamen Univ, 422Siming South Rd, Xiamen 361005, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
Giant congenital melanocytic nevi; Nuclear magnetic resonance; Metabolomics; Metabolic profile; Molecular mechanism; MELANOMA; IDENTIFICATION; METABONOMICS; METABOLITES; ARGININE; PYRUVATE; SERINE;
D O I
10.1016/j.jpba.2024.116060
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Giant congenital melanocytic nevi (GCMN) is a congenital cutaneous developmental deformity tumor that usually occurs at birth or in the first few weeks after birth, but its pathogenesis is still unclear. In this study, nuclear magnetic resonance-based metabolomics strategy was employed to evaluate the metabolic variations in serum and urine of the GCMN patients in order to understand its underlying biochemical mechanism and provide a potential intervention idea. Twenty-nine metabolites were observed to change significantly in serum and urine metabolomes, which are mainly involved in a variety of metabolic pathways including glyoxylate and dicarboxylate metabolism, TCA cycle and metabolisms of amino acids. The substantial cores of all the disturbed metabolic pathways are related to amino acid metabolism and carbohydrate metabolism and regulate the physiological state of the GCMN patients. Our results provide the physiological basis and physiological responses of GCMN and will be helpful for better understanding the molecular mechanisms of GCMN in future research.
引用
收藏
页数:8
相关论文
共 35 条
[1]   Congenital melanocytic nevi: Where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis [J].
Alikhan, Ali ;
Ibrahimi, Omar A. ;
Eisen, Daniel B. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (04) :495.e1-495.e17
[2]   Large or multiple congenital melanocytic nevi: Occurrence of cutaneous melanoma in 1008 persons [J].
Bett, BJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (05) :793-797
[3]   Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis [J].
Bittencourt, FV ;
Marghoob, AA ;
Kopf, AW ;
Koenig, KL ;
Bart, RS .
PEDIATRICS, 2000, 106 (04) :736-741
[4]   Glutamate: a truly functional amino acid [J].
Brosnan, John T. ;
Brosnan, Margaret E. .
AMINO ACIDS, 2013, 45 (03) :413-418
[5]   Aggressive melanoma in an infant with congenital melanocytic nevus syndrome and multiple, NRAS and BRAF mutation-negative nodules [J].
Carrillo, Daniel de la Rosa ;
Vindenes, Harald ;
Kinsler, Veronica A. ;
Ronnestad, Arild ;
Ringstad, Geir ;
Mueller, Lil-Sofie Ording ;
Tafjord, Svetlana ;
Tonseth, Kim A. ;
Kvamme, Bjorn ;
Clausen, Ole Petter Fraas .
PEDIATRIC DERMATOLOGY, 2018, 35 (05) :E281-E285
[6]   EPIDEMIOLOGY OF CONGENITAL PIGMENTED NAEVI .1. INCIDENCE RATES AND RELATIVE FREQUENCIES [J].
CASTILLA, EE ;
DUTRA, MD ;
ORIOLIPARREIRAS, IM .
BRITISH JOURNAL OF DERMATOLOGY, 1981, 104 (03) :307-315
[7]  
Craig SAS, 2004, AM J CLIN NUTR, V80, P539
[8]   Metabolite projection analysis for fast identification of metabolites in metabonomics. Application in an amiodarone study [J].
Dieterle, Frank ;
Ross, Alfred ;
Schlotterbeck, Gotz ;
Senn, Hans .
ANALYTICAL CHEMISTRY, 2006, 78 (11) :3551-3561
[9]   Incidence and distribution of argininosuccinate synthetase deficiency in human cancers - A method for identifying cancers sensitive to arginine deprivation [J].
Dillon, BJ ;
Prieto, VG ;
Curley, SA ;
Ensor, CM ;
Holtsberg, FW ;
Bomalaski, JS ;
Clark, MA .
CANCER, 2004, 100 (04) :826-833
[10]   Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma [J].
Feng, Yongmei ;
Pathria, Gaurav ;
Heynen-Genel, Susanne ;
Jackson, Michael ;
James, Brian ;
Yin, Jun ;
Scott, David A. ;
Ronai, Ze'ev A. .
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (05) :816-832